MarketPulse

Darzalex

2 articles
The Motley FoolThe Motley Fool··Jack Delaney

J&J Beats Earnings but Faces Patent Cliff Reality Check

Johnson & Johnson exceeded Q1 2026 expectations and raised guidance, though stock declined as Stelara patent losses offset strong drug sales.
JNJdividendgeneric competition
BenzingaBenzinga··Vandana Singh

J&J Posts Strong Q1 Earnings Beat on Cancer Drug Surge, but Free Cash Flow Tumbles 56%

Johnson & Johnson beat Q1 earnings expectations with 9.9% revenue growth driven by oncology products, but free cash flow plummeted 55.6% year-over-year.
JNJfree cash flowdividend increase